The IDA Ireland strategy for the pharmaceutical industy in Ireland

Irish Pharmaceutical Healthcare Association (IPHA) Annual Meeting
Barry O’Leary
November 25th 2010

Current Impact of FDI
KEY FDI IMPACTS ON THE IRISH ECONOMY
- €110 BN Exports- 240,000 Jobs in Total- 55% of Corporation Tax
- €19 BN Expenditure
- €7 BN Payroll
- 73% of Business RD&I expenditure
WORLD LEADERS CHOOSE IRELAND
- 8 of the top 10 in ICT - 8 of the top 10 in Pharmaceuticals
- 15 of the top 25 in Medical Devices
- More than 50% of the world’s leading
Financial Services firms
gh

IDA Focus
Business Model Focus
Global Services
High-end Manufacturing
Research, Development & Innovation
Sectors
Life Sciences - Pharma/Biopharma &
- Medical Devices
Information & Communications Technology
Financial Services
Content Industry, Consumer & Business
Services
Diversified Industries and Engineering
CleanTech

FDI 2010 – Recent Wins
Existing Clients

FDI Recent Wins – New Clients

Ireland – major Life Sciences Hub
8 0f the top 10 Pharma
8 of top 10 and 15 of top 25 Medical Technologies
44,000 jobs
Exports €51 Bn p.a.
Numerous sub-suppiier and service providers
Biopharma
Med Tech
Healthcare
Services

Recent Lifesciences FDI Investments
Investing €220m in a new fill finish vaccines facility (170 jobs) Carlow. EMEA Service Centre in Dublin (150 Jobs).
EMEA Shared Services for 100 people, Cork.
Biologics, €400m investment.
250 person manufacturing expansion in Ballina
€30m investment in bio-analytical / chemistry services, 250 Jobs in Athlone
Global manufacturing and development, 204 people, Dundalk
Investing over €160m in R&D in Galway, Cork and Clonmel
100 person manufacturing expansion in Co. Galway
Expansion of €130m and 170 new jobs
European Services Centre in Dublin, creating more than 200 job.
European Shared Services Centre in Cork - 30 jobs
€50 million new manufacturing investment, creating 250 jobs in Clare

Global Lifesciences Industry Drivers/Challenges
Pharma
Patent cliff – increased generics
Pipeline Challenge
Restructuring to accommodate new reality – M&A, cost reduction
Increasing Regulatory hurdles and costs
US Healthcare reform – biosimilars pathway
Biologics
Rise of Asia
Ageing population
Healthcare reform tax
510K regulatory pathway changes USA
Convergence – clear coupling of devices and tech.
Asian market growing strongly

Demand for healthcare to continue to grow
Ageing population
20%+ of population will be over 65 in developed markets by 2025
Emerging markets
Pharma market expected to double by 2015
Increasing demand
Unmet needs
Oncology, immunology, antiviral HIV, stroke, Alzheimer's, obesity, thrombosis, HCV
Copyright © 2010 by The Boston Consulting Group, Inc. All rights reserved.
New technologies
Broaderoffer
e.g., Predictive technologies, such as biomarkers, in silico models
1. Source : IMS Market prognosis
9

Evolution of Pharma Bio
2020
1980s
1990s
2000s
Commodity medicines
Self-Dx, Self Treat
Nutraceuticals
Convergent technologies
Connected Health
Personalised Medicine
Combination medical products
Medical Services
Single Platform Technology
API manufacturing
Q&A labs
Sophisticated manufacturing
Liquids
Tabletting
Creams
Patches
Molecular diagnostics
Reference Global Sites
Biopharma
Shared services - Supply chain, Regulatory, Finance

11
Horizon 2020 - Ongoing Evolution of Pharma Bio
2010-2015- Capturing and Delivering marketplace opportunites
Integrating disease with lifestyle management
Leveraging expertise in nutraceuticals, point of care assays
Advancing molecular diagnostics and targetted therapies
Utilising genetic testing & biomarkers in advanced clinical trials
Developing convergent medical products
Rise of bioinfomatics, population health strategies
Now - Building and Developing the sector
Winning new biopharmainvestments
Leveraging NiBRT to advance BiopharmaIndustry
Enhancing Ireland’s small molecule Value Proposition
Support vaccine development, generic reformulation, improved drug delivery
Expanding mandates of top 30 companies “start earlier-finish later”
Supporting new starts in packaging, tabletting, labelling, supply chain
Expanding footprints into shared services, commercialisation, clinical trials

12
Horizon 2020 - Ongoing Evolution of Pharma Bio
2020 Foresight
Convergent medical management – drug & dynamic device
Regenerative Health platforms in ageing, organ, joint replacement
Connected Health platforms integrating e-health
Cancer vaccines, targeted personal therapies
Advancing silver care, aged care, focus on mental wellness
Tailored health insurance per decade of life
Development of “polypill”
Integrated digital medical record and decision support
Remote monitoring and treatment at home
New bioactive materials and molecules from marine ecosystem

Ireland : A Proven Location for
Lifesciences Service Activities

Initiatives to protect and grow Industry
Transformation –
Technology uplift,
Skills uplift
Process development
Product Development
Energy Efficiency
Operational excellence
Strategic Sites and CMO
NIBRT for Bio
National Commercialisation centre for medical devices
National competence centre for small molecule production
International healthcare services centre
Healthcare Innovation hub with HSE
Research and Development Agenda

Integrated Communications Campaign
TV Ads
Live TV Interviews
Online Media
Print Media
Airport Posters
Press Interviews
Web Optimisation

Professor Luke O’Neill – Trinity College Dublin

IDA TV Ad – 30 Secs

Thank You

The IDA Ireland strategy for the pharmaceutical industy in Ireland

by Irish Pharmaceutical Healthcare Association (IPHA) on Nov 26, 2010

Accessibility

Categories

Upload Details

Usage Rights

1 Embed 39

Statistics

The IDA Ireland strategy for the pharmaceutical industy in Ireland Webinar Transcript